Amyndas Pharmaceuticals S.A

Despina Yancopoulou, PhD, MDA, Managing Director 

Dr Yancopoulou has a combined science and business background and several years of experience in technology transfer, in the process of translating scientific advances into innovative products for unmet medical needs. 

Amyndas is a small pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system. The company is committed to developing the most advanced therapies to treat inflammatory disorders, in particular orphan diseases and conditions representing areas of unmet medical need for which patients need better and safer therapies. 

Amyndas is founded on the world-class science and expertise of Dr. John Lambris, a world leader in complement research, with 30 years experience in the complement field, over 450 scientific publications in top journals and the inventor of a broad IP portfolio. The company is also supported by an international network of scientific, clinical and industry experts with strong experience in the clinical development process and a proven track record of bringing compounds from discovery through to the clinic.

Amyndas has programs in Transplantation, the rare hemolytic disease Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 glomerulopathy, Periodontitis, Age-Related Macular Degeneration, Hemodialysis and Ischemia/Reperfusion Injuries.

For the development of AMY-101 in ABO-incompatible (ABOi) kidney transplantation, Amyndas participates in the EU funded FP7 project DIREKT, a collaborative project of 12 European partners, headed by the University of Uppsala.